To investigate the influence of specific gene polymorphisms on the lipid response to rosuvastatin therapy.
Conducted a meta-analysis of existing studies focusing on SLCO1B1, ApoE, and ABCG2 gene polymorphisms.
Analyzed data related to LDL-C levels in relation to these genetic variants.
Included various clinical studies examining the efficacy of rosuvastatin across different populations.
Identified that SLCO1B1, ApoE, and ABCG2 polymorphisms significantly affect LDL-C reduction.
The c.388A>G variant in SLCO1B1, along with ApoE and ABCG2 variations, shows a strong correlation with lipid response.
Individuals carrying specific polymorphisms may require adjusted rosuvastatin dosing for optimal lipid management.
Abstract
The lipid-lowering efficacy of rosuvastatin (especially the reduction of LDL-C level) is significantly affected by the polymorphisms of SLCO1B1 (c.388A>G), ApoE (c.388T>C, c.526C>T) and ABCG2 (c.421C>A) genes.